The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients. (Q54619423)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author

Kamila Wojas-Krawczyk

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Paweł Krawczyk

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Radosław Mlak

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Tomasz Kucharczyk

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Dariusz M Kowalski

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Maciej Krzakowski

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

7

Janusz Milanowski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

18 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

341-350

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21242665%20AND%20SRC:MED&resulttype=core&format=json

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

20 January 2020

cites work

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.

21 January 2018

1 reference

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

21 January 2018

1 reference

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

EGFR testing in lung cancer is ready for prime time

21 January 2018

1 reference

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

21 January 2018

1 reference

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib

21 January 2018

1 reference

Molecular pathology of non-small-cell lung cancer

21 January 2018

1 reference

MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer

21 January 2018

1 reference

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study

21 January 2018

1 reference

The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.

21 January 2018

1 reference